Skip to content
10-Q

Quarterly Report

BIOCRYST PHARMACEUTICALS INC BCRX

0001628280-25-048785

← back to feed
Filed
Nov 4, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 31, 2025 210.54M sh
Shares Diluted Q3 2025 · Sep 30, 2025 219.89M sh
Shares Diluted Q3 2025 · Sep 30, 2025 218.35M sh
Shares Diluted Q3 2025 · Sep 30, 2024 206.91M sh
Shares Diluted Q3 2025 · Sep 30, 2024 206.47M sh
Operating Cash Flow Q3 2025 · Sep 30, 2025 $55.41M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$46.81M
Long Term Debt Q3 2025 · Sep 30, 2025 $194.37M
Long Term Debt Q3 2025 · Dec 31, 2024 $314.87M
Short Term Investments Q3 2025 · Sep 30, 2025 $128.8M
Short Term Investments Q3 2025 · Dec 31, 2024 $216.14M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $84.08M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $104.71M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $96.84M
Stockholders Equity Q3 2025 · Sep 30, 2025 −$387.89M
Stockholders Equity Q3 2025 · Jun 30, 2025 −$421.59M
Stockholders Equity Q3 2025 · Mar 31, 2025 −$451.93M
Stockholders Equity Q3 2025 · Dec 31, 2024 −$475.93M
Stockholders Equity Q3 2025 · Sep 30, 2024 −$468.56M
Stockholders Equity Q3 2025 · Jun 30, 2024 −$475.61M
Stockholders Equity Q3 2025 · Mar 31, 2024 −$476.17M
Stockholders Equity Q3 2025 · Dec 31, 2023 −$455.53M
Current Liabilities Q3 2025 · Sep 30, 2025 $190.24M
Current Liabilities Q3 2025 · Dec 31, 2024 $160.38M
Total Liabilities Q3 2025 · Sep 30, 2025 $834.31M
Total Liabilities Q3 2025 · Dec 31, 2024 $966.35M
Current Assets Q3 2025 · Sep 30, 2025 $355.68M
Current Assets Q3 2025 · Dec 31, 2024 $421.97M
Total Assets Q3 2025 · Sep 30, 2025 $446.42M
Total Assets Q3 2025 · Dec 31, 2024 $490.42M
Eps Diluted Q3 2025 · Sep 30, 2025 $0.06
Eps Diluted Q3 2025 · Sep 30, 2025 $0.08
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.07
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.30
Eps Basic Q3 2025 · Sep 30, 2025 $0.06
Eps Basic Q3 2025 · Sep 30, 2025 $0.09
Eps Basic Q3 2025 · Sep 30, 2024 −$0.07
Eps Basic Q3 2025 · Sep 30, 2024 −$0.30
Sga Expense Q3 2025 · Sep 30, 2025 $83.01M
Sga Expense Q3 2025 · Sep 30, 2025 $252.87M
Sga Expense restated Q3 2025 · Sep 30, 2024 $65.1M
Sga Expense restated Q3 2025 · Sep 30, 2024 $185.84M
Rd Expense Q3 2025 · Sep 30, 2025 $44.6M
Rd Expense Q3 2025 · Sep 30, 2025 $125.26M
Rd Expense Q3 2025 · Sep 30, 2024 $41.08M
Rd Expense Q3 2025 · Sep 30, 2024 $125.2M
Net Income Q3 2025 · Sep 30, 2025 $12.9M
Net Income Q3 2025 · Sep 30, 2025 $18.02M
Net Income Q3 2025 · Jun 30, 2025 $5.09M
Net Income Q3 2025 · Mar 31, 2025 $32K
Net Income Q3 2025 · Sep 30, 2024 −$14.03M
Net Income Q3 2025 · Sep 30, 2024 −$62.09M
Net Income Q3 2025 · Jun 30, 2024 −$12.67M
Net Income Q3 2025 · Mar 31, 2024 −$35.38M
Operating Income Q3 2025 · Sep 30, 2025 $29.59M
Operating Income Q3 2025 · Sep 30, 2025 $80.6M
Operating Income Q3 2025 · Sep 30, 2024 $7.69M
Operating Income Q3 2025 · Sep 30, 2024 $1.97M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $2.19M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $9.55M
Cost Of Revenue Q3 2025 · Sep 30, 2024 $3.21M
Cost Of Revenue Q3 2025 · Sep 30, 2024 $6.18M